Man Group’s Forte Biosciences FBRX Stock Holding History

Man Group’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-430	Closed	-$12K	–	2050
2022 Q3	$12K	Buy	+430	New	+$13.7K	﹤0.01%	1969

Other funds holding FBRX

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

OWP

Old Well Partners Charlotte, North Carolina $4.55M AUM 27.75% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Man Group's FBRX Position: Q4 2022 in Review

Man Group sold out of Forte Biosciences (FBRX) in Q4 2022, closing a stake of 430 shares — an estimated $12K sold.

Man Group first reported a position in FBRX in Q3 2022 and held it in 1 quarter. The position peaked at $12K in Q3 2022. 34 funds tracked by Wall St. Rank hold FBRX as of Q4 2022.

Man Group reported no remaining Forte Biosciences position as of Q4 2022 after selling out during the quarter.
Man Group sold 430 Forte Biosciences shares in Q4 2022, an estimated $12K.
Man Group first reported a position in Forte Biosciences in Q3 2022 and held it in 1 quarter.
Man Group's Forte Biosciences position peaked at $12K in Q3 2022.
34 funds tracked by Wall St. Rank held Forte Biosciences as of Q4 2022.

Based on Man Group's 13F filing for Q4 2022, filed 14 Feb 2023.